The acquisition of Dren Bio's bispecific myeloid cell engager is a strategic move by Sanofi to enhance its immunology pipeline. The $600 million investment indicates a significant commitment to becoming a leader in the immunology sector. This acquisition is likely to positively impact Sanofi's stock price in the short term as it strengthens its product offerings and market position.